![logo](/logos/INKT.webp)
MiNK Therapeutics, Inc.
NASDAQ:INKT
0.79 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | MiNK Therapeutics, Inc. |
Symbool | INKT |
Munteenheid | USD |
Prijs | 0.788 |
Beurswaarde | 31,169,138 |
Dividendpercentage | 0% |
52-weken bereik | 0.75 - 1.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jennifer S. Buell Ph.D. |
Website | https://minktherapeutics.com |
An error occurred while fetching data.
Over MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)